Symbols

CRSP

CRISPR Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

Negative Gross Margin

Significant Revenue Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CRSP

Crispr Therapeutics Ag

A biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases

Industry

Biological Technology

Established Date

10/31/2013

Listing Date

10/19/2016

Exchange

NASDAQ Stock Exchange

Full-time Employees

393

Fiscal Year Ends

12-31

Website

www.crisprtx.com

Security Type

Common stock

Office address

Baarerstrasse 14, 6300 Zug, Switzerland

Business

Introduction

CRISPR Therapeutics AG was incorporated as a Swiss joint stock company under Inception Genomics AG on October 31, 2013. They are a leading genetic research company focusing on the development of CRISPR/Cas 9 therapies. CRISPR/Cas 9 stands for Cluster, Periodically Interspaced Short Palindrome Repeat (CRISPR) Related Protein 9, a revolutionary technology in the process of altering the arrangement of genes and the specific sequence of genomic DNA. They are applying this technique to treat a wide range of rare or common diseases by disrupting, correcting or modulating disease-related genes. Their most advanced project is for β-thalassemia and sickle cell disease, the treatment of which requires two hemoglobins for high medical needs.

Company Financials

EPS

CRSP has released its 2025 Q3 earnings. EPS was reported at -1.17, versus the expected -1.29, beating expectations. The chart below visualizes how CRSP has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CRSP has released its 2025 Q3 earnings report, with revenue of 889.00K, reflecting a YoY change of 47.67%, and net profit of -106.44M, showing a YoY change of -23.85%. The Sankey diagram below clearly presents CRSP's revenue sources and cost distribution.